|
| ||||||||||||||
RedChip Announces Duska Therapeutics CEO Television Interview Available Online ORLANDO, Fla., Nov. 13, 2007 (PRIME NEWSWIRE) -- Duska Therapeutics,
Inc. (OTC BB:DSKA.OB - News), a biopharmaceutical company developing
new medicines to treat cardiovascular, pulmonary, neural
and renal diseases, announced that the company's CEO, Dr.
James Kuo, was interviewed on RedChip TV, a business-oriented
television interview program. The interview illuminated
the company's strategies for developing diagnostic and therapeutic
products to treat various human disorders, including male
infertility and pulmonary diseases. The full interview is
available at: If you have trouble connecting via the link, cut and paste the entire address into your browser address window. The interview was conducted Nov. 3, 2007, in conjunction with the company's presentation at RedChip's Small-Cap Investor Conference in Orlando, Fla. Duska Therapeutics's entire presentation to the analysts and brokers and individual investors at the conference -- including PowerPoint slides -- can be viewed by clicking on the following link: If you have trouble connecting via the link, cut and paste the entire address into your browser address window. About Duska Therapeutics, Inc. Duska Therapeutics, Inc., based in Bala Cynwyd, Pennsylvania, develops new medicines to treat cardiovascular diseases by modulating the P2 receptor in the heart and lungs. In addition to ATPace(tm) (adenosine triphosphate injection) for the treatment and diagnosis of certain cardiac arrhythmias, Duska has drug development programs targeting chronic obstructive pulmonary disorders and cough, male infertility and mitigating the toxic effects of radiation exposure. For more information, visit Duska's website: http://www.duskatherapeutics.com. About RedChip Companies Inc. RedChip Companies is an international small-cap research and financial public relations firm with offices in Beijing and Orlando and affiliates in New York and San Diego. RedChip delivers measurable results for its clients through its extensive international market expertise as well as its comprehensive platform of products: RedChip Research(tm), Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences held throughout the United States, and RedChip Radio(tm). To learn more about RedChip's products and services please visit: http://www.redchip.com/visibility/services.asp. ``Discovering Tomorrow's Blue Chips Today''(tm) The RedChip Companies Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=2761 DISCLOSURE Duska Therapeutics is a client of the RedChip Companies Inc. and has contracted the RedChip Companies to increase investor awareness of DSKA to the small-cap equity community. These services may include investor conferences and digital print distribution of DSKA investor related materials. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by the Company. RedChip Companies Inc. receives a monthly fee of $6,000 and receives 30,000 shares of common stock under Rule 144 stock for investor relations services. Contact: RedChip Companies Inc.
Jon Cunningham
1(800) RED-CHIP (733-2447) ext. 107
jon@RedChip.com
info@redchip.com
www.RedChip.com
Duska Therapeutics, Inc.
General Information:
Wayne Lorgus, Chief Financial Officer
(610) 660-6690
Source: RedChip Companies Inc.; Duska Therapeutics, Inc.
|  | |||||||||||||
